Affimed ASCO Data Demonstrate Consistent Potency of NK- Cell-Engaging Combination Therapy with Checkpoint Modulators May 29, 2015
Affimed ASCO Data for the CD33/CD3-TandAb Program Demonstrate that CD33 and CD3 binding affinities correlate with potent T-cell activation and cytotoxicity May 29, 2015
Affimed Completes TandAb Development Candidate Activities Meeting Amphivena’s and Janssen’s Criteria and Achieves Milestone Ahead of Schedule May 24, 2015
Affimed to Present Data at ASCO to Highlight Potency of NK- Cell-Engaging Combination Therapy with Checkpoint Modulators May 13, 2015
Affimed N.V. Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Option to Purchase Additional Shares May 12, 2015
